- Home
- ACIC vs CAPR Comparison
ACIC vs CAPR Comparison
Compare ACIC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- CAPR
- Stock Information
- Founded
- ACIC 1999
- CAPR 2005
- Country
- ACIC United States
- CAPR United States
- Employees
- ACIC N/A
- CAPR N/A
- Industry
- ACIC Property-Casualty Insurers
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIC Finance
- CAPR Health Care
- Exchange
- ACIC Nasdaq
- CAPR Nasdaq
- Market Cap
- ACIC 569.8M
- CAPR 578.4M
- IPO Year
- ACIC N/A
- CAPR N/A
- Fundamental
- Price
- ACIC $12.51
- CAPR $15.00
- Analyst Decision
- ACIC Buy
- CAPR Strong Buy
- Analyst Count
- ACIC 1
- CAPR 7
- Target Price
- ACIC $16.00
- CAPR $39.29
- AVG Volume (30 Days)
- ACIC 120.2K
- CAPR 881.0K
- Earning Date
- ACIC 02-27-2025
- CAPR 03-03-2025
- Dividend Yield
- ACIC 3.99%
- CAPR N/A
- EPS Growth
- ACIC N/A
- CAPR N/A
- EPS
- ACIC 1.76
- CAPR N/A
- Revenue
- ACIC $290,784,000.00
- CAPR $23,228,045.00
- Revenue This Year
- ACIC N/A
- CAPR N/A
- Revenue Next Year
- ACIC $12.68
- CAPR $74.85
- P/E Ratio
- ACIC $7.11
- CAPR N/A
- Revenue Growth
- ACIC 1.02
- CAPR 65.33
- 52 Week Low
- ACIC $8.82
- CAPR $3.52
- 52 Week High
- ACIC $15.08
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- ACIC 51.61
- CAPR 52.56
- Support Level
- ACIC $11.66
- CAPR $14.28
- Resistance Level
- ACIC $13.50
- CAPR $16.47
- Average True Range (ATR)
- ACIC 0.44
- CAPR 1.00
- MACD
- ACIC 0.11
- CAPR 0.07
- Stochastic Oscillator
- ACIC 46.20
- CAPR 55.05
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.